Filing Details
GYRE THERAPEUTICS, INC. (NASDAQ:GYRE) filed a Form 8-K with the Securities and Exchange Commission on August 07, 2026, disclosing a material event.
8k filedNASDAQ:GYRE
GYRE THERAPEUTICS, INC. (GYRE) Reports Material Event to SEC
GYRE THERAPEUTICS, INC. (NASDAQ:GYRE) filed a Form 8-K with the Securities and Exchange Commission on August 07, 2026, disclosing a material event.
At publication ·
What changed
GYRE THERAPEUTICS, INC. (NASDAQ:GYRE) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Gyre Therapeutics filed a Form 8-K with the SEC on August 7, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing summary.
- The company's stock was trading at $6.67 per share with a market capitalization of $715.9 million at the time of the disclosure.
Market Context
GYRE THERAPEUTICS, INC.'s stock currently trades at $6.67 with a market capitalization of $715.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for GYRE THERAPEUTICS, INC.'s stock.
All SEC filings for GYRE THERAPEUTICS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View GYRE Stock Page
Frequently Asked Questions
Where can I read GYRE's SEC filings?
Browse all filings on our GYRE SEC filings page.
What types of SEC filings does GYRE THERAPEUTICS, INC. file?
Public companies like GYRE THERAPEUTICS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.